16.75 USD
-1.3 (-7.2%)
Taking everything into account, PRTC scores 3 out of 10 in our fundamental rating. PRTC was compared to 531 industry peers in the Biotechnology industry. While PRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PRTC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PRTC had negative earnings in the past year.
PRTC had a negative operating cash flow in the past year.
In multiple years PRTC reported negative net income over the last 5 years.
PRTC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 9.16%, PRTC belongs to the best of the industry, outperforming 93.41% of the companies in the same industry.
With an excellent Return On Equity value of 13.48%, PRTC belongs to the best of the industry, outperforming 94.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROIC | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PRTC (792.96%) is better than 99.25% of its industry peers.
In the last couple of years the Profit Margin of PRTC has declined.
The Operating Margin and Gross Margin are not available for PRTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTC has been reduced compared to 1 year ago.
The number of shares outstanding for PRTC has been reduced compared to 5 years ago.
Compared to 1 year ago, PRTC has a worse debt to assets ratio.
2.2 Solvency
PRTC has an Altman-Z score of 1.76. This is a bad value and indicates that PRTC is not financially healthy and even has some risk of bankruptcy.
PRTC has a Altman-Z score of 1.76. This is in the better half of the industry: PRTC outperforms 65.54% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that PRTC is not too dependend on debt financing.
PRTC has a worse Debt to Equity ratio (0.05) than 60.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.76 |
ROIC/WACCN/A
WACC8.53%
2.3 Liquidity
PRTC has a Current Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 75.71% of the companies in the same industry.
PRTC has a Quick Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 75.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 168.34% over the past year.
Measured over the past years, PRTC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -32.49% on average per year.
The Revenue has grown by 1265.60% in the past year. This is a very strong growth!
The Revenue for PRTC have been decreasing by -13.22% on average. This is quite bad
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
3.2 Future
The Earnings Per Share is expected to decrease by -16.77% on average over the next years. This is quite bad
The Revenue is expected to grow by 223.14% on average over the next years. This is a very strong growth
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRTC's earnings are expected to decrease with -17.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
5. Dividend
5.1 Amount
No dividends for PRTC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PRTC (12/8/2025, 4:10:04 PM)
16.75
-1.3 (-7.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners72.05%
Inst Owner Change3919.71%
Ins Owners4.86%
Ins Owner ChangeN/A
Market Cap404.82M
Revenue(TTM)6.39M
Net Income(TTM)50.68M
Analysts84
Price Target67.76 (304.54%)
Short Float %0.03%
Short Ratio1.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.19%
PT rev (3m)-4.98%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 63.34 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.08 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.27
EYN/A
EPS(NY)-6.52
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.26
BVpS15.56
TBVpS15.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 | ||
| Altman-Z | 1.76 |
F-Score7
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)9.91%
Cap/Depr(5y)37.78%
Cap/Sales(3y)7.17%
Cap/Sales(5y)20.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
EBIT growth 1Y13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.57%
EBIT Next 3Y-5.38%
EBIT Next 5Y3.12%
FCF growth 1Y36.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.98%
OCF growth 3YN/A
OCF growth 5YN/A
PURETECH HEALTH PLC - ADR / PRTC FAQ
Can you provide the ChartMill fundamental rating for PURETECH HEALTH PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to PRTC.
What is the valuation status for PRTC stock?
ChartMill assigns a valuation rating of 0 / 10 to PURETECH HEALTH PLC - ADR (PRTC). This can be considered as Overvalued.
What is the profitability of PRTC stock?
PURETECH HEALTH PLC - ADR (PRTC) has a profitability rating of 3 / 10.
Can you provide the financial health for PRTC stock?
The financial health rating of PURETECH HEALTH PLC - ADR (PRTC) is 5 / 10.
Is the dividend of PURETECH HEALTH PLC - ADR sustainable?
The dividend rating of PURETECH HEALTH PLC - ADR (PRTC) is 0 / 10 and the dividend payout ratio is 0%.